Ipratropium/Levalbuterol

异丙托铵/左沙丁胺醇

Report date: 2023/06/07 20:00:31

Base Information

Drug NameIpratropium/Levalbuterol
Drug Alias NameIpratropium and Levalbuterol异丙托铵+左沙丁胺醇Ipratropium-Levalbuterol mixt左沙丁胺醇/异丙托铵Levalbuterol /Ipratropium +[15] 
ClassificationSmall molecules
Mechanisms of ActionBeta-2 adrenergic receptor agonistsMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptorBeta-2 adrenergic receptor
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveBronchial Spasm
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTurkeyMainland China
CombinationsYes Ipratropium bromideLevosalbutamol
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSumitomo Dainippon
China Registration ClassN/A

Develop Information

Active CompaniesNeutec Ar-Ge San Ve Tic A.ŞJiangsu Hechen Pharmaceutical Co Ltd
Inactive CompaniesSumitomo Dainippon
Active IndicationsPulmonary Disease, Chronic ObstructiveBronchial Spasm
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A